<?xml version="1.0" encoding="UTF-8"?>
<p>Spirooxindoles 
 <bold>6a–p</bold> were tested for their 
 <italic>in vitro</italic> anti-HCC activity against HepG2 cell line, and for their anti-prostate cancer activity against PC-3 cell line by the use of MTT reduction assay
 <xref rid="CIT0027" ref-type="bibr">
  <sup>27</sup>
 </xref>. The anticancer drug Adriamycin was co-assayed as the positive control. The anti-proliferative activities of tested spirooxindoles against the two cancer cell lines were measured as IC
 <sub>50</sub> (in μM) value (the dose that affords a 50% inhibition of cell growth after 48 h of incubation) and displayed in 
 <xref rid="t0001" ref-type="table">Table 1</xref>.
</p>
